◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › ALEC

Alector, Inc. (ALEC) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-26

Alector, Inc. (ALEC) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 103 employees. Its market capitalization is roughly $164 million. In the fiscal year ended 2025-12-31, ALEC reported $21M in revenue and ($143M) in net income.

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.

Interactive charts & full statements → Open the ALEC valuation workbench →

ALEC Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$21M$101M$97M$134M
Operating Income (EBIT)($156M)($145M)($152M)($138M)
Net Income($143M)($119M)($130M)($133M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALEC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$1M$6M$3M$8M$4M
Operating Income (EBIT)($25M)($40M)($38M)($34M)($45M)
Net Income($23M)($37M)($35M)($30M)($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ALEC Free Cash Flow History

ALEC Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$293M$468M$622M$788M
Total Liabilities$263M$342M$488M$573M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALEC viewer.

Other Companies in Biotechnology

← ALDXAll stocksALF →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.